Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain

Alessandra Fraternale, Maria Filomena Paoletti, Anna Casabianca, Chiara Orlandi, Enrico Millo, Emanuela Balestra, Gianluca Damonte, Carlo Federico Perno, Mauro Magnani

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

PNAPR2 is a peptide nucleic acid (PNA) complementary to a sequence of the viral protease-encoding gene, effective in blocking HIV release, when used at high doses. Erythrocytes (RBC) were used to target PNA PR2 to the macrophage compartment. The antiviral activity was assessed in human HIV-infected macrophages both as inhibition of p24 production and reduction of HIV DNA content. PNAPR2, either added to the medium at a concentration of 100 μM or loaded into RBC at about 40 μM, inhibited p24 production 80 compared with infected samples and reduced HIV DNA content by 83 and 90, respectively. The results show that (1) a stronger anti-HIV effect is achievable with higher doses of PNAPR2, both when given free and encapsulated into RBC; (2) the antiviral effect obtained by free PNA PR2 at a concentration of 100 μM is achievable by encapsulating it into RBC at a concentration of 40 μM, suggesting that RBC can be used as a delivery system to increase the antisense effect of PNAPR2.

Original languageEnglish
Pages (from-to)278-285
Number of pages8
JournalJournal of Drug Targeting
Volume17
Issue number4
DOIs
Publication statusPublished - May 2009

Fingerprint

Peptide Nucleic Acids
HIV-1
Erythrocytes
HIV
Antiviral Agents
Macrophages
DNA
Peptide Hydrolases
Genes

Keywords

  • Delivery
  • Erythrocytes (RBC)
  • HIV
  • Macrophages
  • Peptide nucleic acid (PNA)

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Fraternale, A., Paoletti, M. F., Casabianca, A., Orlandi, C., Millo, E., Balestra, E., ... Magnani, M. (2009). Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain. Journal of Drug Targeting, 17(4), 278-285. https://doi.org/10.1080/10611860902737474

Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain. / Fraternale, Alessandra; Paoletti, Maria Filomena; Casabianca, Anna; Orlandi, Chiara; Millo, Enrico; Balestra, Emanuela; Damonte, Gianluca; Perno, Carlo Federico; Magnani, Mauro.

In: Journal of Drug Targeting, Vol. 17, No. 4, 05.2009, p. 278-285.

Research output: Contribution to journalArticle

Fraternale, A, Paoletti, MF, Casabianca, A, Orlandi, C, Millo, E, Balestra, E, Damonte, G, Perno, CF & Magnani, M 2009, 'Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain', Journal of Drug Targeting, vol. 17, no. 4, pp. 278-285. https://doi.org/10.1080/10611860902737474
Fraternale A, Paoletti MF, Casabianca A, Orlandi C, Millo E, Balestra E et al. Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain. Journal of Drug Targeting. 2009 May;17(4):278-285. https://doi.org/10.1080/10611860902737474
Fraternale, Alessandra ; Paoletti, Maria Filomena ; Casabianca, Anna ; Orlandi, Chiara ; Millo, Enrico ; Balestra, Emanuela ; Damonte, Gianluca ; Perno, Carlo Federico ; Magnani, Mauro. / Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain. In: Journal of Drug Targeting. 2009 ; Vol. 17, No. 4. pp. 278-285.
@article{3e7821dd9db543bba2590e91c4221506,
title = "Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain",
abstract = "PNAPR2 is a peptide nucleic acid (PNA) complementary to a sequence of the viral protease-encoding gene, effective in blocking HIV release, when used at high doses. Erythrocytes (RBC) were used to target PNA PR2 to the macrophage compartment. The antiviral activity was assessed in human HIV-infected macrophages both as inhibition of p24 production and reduction of HIV DNA content. PNAPR2, either added to the medium at a concentration of 100 μM or loaded into RBC at about 40 μM, inhibited p24 production 80 compared with infected samples and reduced HIV DNA content by 83 and 90, respectively. The results show that (1) a stronger anti-HIV effect is achievable with higher doses of PNAPR2, both when given free and encapsulated into RBC; (2) the antiviral effect obtained by free PNA PR2 at a concentration of 100 μM is achievable by encapsulating it into RBC at a concentration of 40 μM, suggesting that RBC can be used as a delivery system to increase the antisense effect of PNAPR2.",
keywords = "Delivery, Erythrocytes (RBC), HIV, Macrophages, Peptide nucleic acid (PNA)",
author = "Alessandra Fraternale and Paoletti, {Maria Filomena} and Anna Casabianca and Chiara Orlandi and Enrico Millo and Emanuela Balestra and Gianluca Damonte and Perno, {Carlo Federico} and Mauro Magnani",
year = "2009",
month = "5",
doi = "10.1080/10611860902737474",
language = "English",
volume = "17",
pages = "278--285",
journal = "Journal of Drug Targeting",
issn = "1061-186X",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain

AU - Fraternale, Alessandra

AU - Paoletti, Maria Filomena

AU - Casabianca, Anna

AU - Orlandi, Chiara

AU - Millo, Enrico

AU - Balestra, Emanuela

AU - Damonte, Gianluca

AU - Perno, Carlo Federico

AU - Magnani, Mauro

PY - 2009/5

Y1 - 2009/5

N2 - PNAPR2 is a peptide nucleic acid (PNA) complementary to a sequence of the viral protease-encoding gene, effective in blocking HIV release, when used at high doses. Erythrocytes (RBC) were used to target PNA PR2 to the macrophage compartment. The antiviral activity was assessed in human HIV-infected macrophages both as inhibition of p24 production and reduction of HIV DNA content. PNAPR2, either added to the medium at a concentration of 100 μM or loaded into RBC at about 40 μM, inhibited p24 production 80 compared with infected samples and reduced HIV DNA content by 83 and 90, respectively. The results show that (1) a stronger anti-HIV effect is achievable with higher doses of PNAPR2, both when given free and encapsulated into RBC; (2) the antiviral effect obtained by free PNA PR2 at a concentration of 100 μM is achievable by encapsulating it into RBC at a concentration of 40 μM, suggesting that RBC can be used as a delivery system to increase the antisense effect of PNAPR2.

AB - PNAPR2 is a peptide nucleic acid (PNA) complementary to a sequence of the viral protease-encoding gene, effective in blocking HIV release, when used at high doses. Erythrocytes (RBC) were used to target PNA PR2 to the macrophage compartment. The antiviral activity was assessed in human HIV-infected macrophages both as inhibition of p24 production and reduction of HIV DNA content. PNAPR2, either added to the medium at a concentration of 100 μM or loaded into RBC at about 40 μM, inhibited p24 production 80 compared with infected samples and reduced HIV DNA content by 83 and 90, respectively. The results show that (1) a stronger anti-HIV effect is achievable with higher doses of PNAPR2, both when given free and encapsulated into RBC; (2) the antiviral effect obtained by free PNA PR2 at a concentration of 100 μM is achievable by encapsulating it into RBC at a concentration of 40 μM, suggesting that RBC can be used as a delivery system to increase the antisense effect of PNAPR2.

KW - Delivery

KW - Erythrocytes (RBC)

KW - HIV

KW - Macrophages

KW - Peptide nucleic acid (PNA)

UR - http://www.scopus.com/inward/record.url?scp=70749123774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70749123774&partnerID=8YFLogxK

U2 - 10.1080/10611860902737474

DO - 10.1080/10611860902737474

M3 - Article

C2 - 19255894

AN - SCOPUS:70749123774

VL - 17

SP - 278

EP - 285

JO - Journal of Drug Targeting

JF - Journal of Drug Targeting

SN - 1061-186X

IS - 4

ER -